Passa al contenuto
Merck

Predicting disease progression from short biomarker series using expert advice algorithm.

Scientific reports (2015-05-21)
Kai Morino, Yoshito Hirata, Ryota Tomioka, Hisashi Kashima, Kenji Yamanishi, Norihiro Hayashi, Shin Egawa, Kazuyuki Aihara
ABSTRACT

Well-trained clinicians may be able to provide diagnosis and prognosis from very short biomarker series using information and experience gained from previous patients. Although mathematical methods can potentially help clinicians to predict the progression of diseases, there is no method so far that estimates the patient state from very short time-series of a biomarker for making diagnosis and/or prognosis by employing the information of previous patients. Here, we propose a mathematical framework for integrating other patients' datasets to infer and predict the state of the disease in the current patient based on their short history. We extend a machine-learning framework of "prediction with expert advice" to deal with unstable dynamics. We construct this mathematical framework by combining expert advice with a mathematical model of prostate cancer. Our model predicted well the individual biomarker series of patients with prostate cancer that are used as clinical samples.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Trietilammina, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
Trietilammina, ≥99.5%
Sigma-Aldrich
Trietilammina, ≥99%
Sigma-Aldrich
Trietilammina, ≥99.5%
Sigma-Aldrich
Trietilammina, puriss. p.a., ≥99.5% (GC)
Sigma-Aldrich
Trietilammina, for protein sequence analysis, ampule, ≥99.5% (GC)
Sigma-Aldrich
Trietilammina, for amino acid analysis, ≥99.5% (GC)